Controlled Release in Oral Drug Delivery
Controlling the rate, extent and time of a drug’s delivery can optimize its performance in many ways, relative to “immediate release” delivery. Such optimized design requires a broad knowledge base of topics such as gastro intestinal tract physiology, pol
- PDF / 1,553,349 Bytes
- 11 Pages / 439.37 x 666.142 pts Page_size
- 88 Downloads / 230 Views
Patrick Crowley (http://www.callumconsultancy.com) Patrick Crowley has over 40 years of experience in dosage form development in the pharmaceutical industry, in both the UK and the USA. He has played key roles in the development of 16 commercial products, including fermentation products, semisynthetics, synthetic structures and a biopharmaceutical product and holds several formulation-related patents. His interests and publications include drug and product stability, enhancing performance by dosage form design and the application of quality-by-design principles and practices in dosage form development, manufacture and control. Clive G. Wilson, Ph.D., F.A.P.S. (Hons), F.C.R.S. Clive Wilson is the J.P. Todd Professor of Pharmaceutics at Strathclyde University in Glasgow, Scotland, and the current president of the European Union Federation for Pharmaceutical Sciences. He is the chief scientist of Bio-Images Research Group, a phase II imaging specialist clinical unit in Glasgow Royal Infirmary. His major areas of research have been the study of the behaviour of drug formulations in man. With colleagues at Nottingham, he pioneered applications of scintigraphy in the study of physiological and pathophysiological effects of transit on drug absorption and began the investigations into regional drug absorption in man. This was later applied to the design and optimisation of oral dosage forms, in silico modelling of formulations in man and studies on IVIVR. He has published more than 150 papers, 6 books and over 130 reviews and book chapters. He was made a fellow of the Controlled Release Society in June 2010 and a fellow of the Academy of Pharmaceutical Sciences in September 2010.
C.G. Wilson and P.J. Crowley (eds.), Controlled Release in Oral Drug Delivery, Advances in Delivery Science and Technology, DOI 10.1007/978-1-4614-1004-1, © Controlled Release Society 2011
401
Index
A Absorption, drug. See Extrudable technologies, drug absorption; Gut and oral absorption, drugs Acrylic copolymers (Eudragit®), 252–253 Aerosil® controlled drug release, 16–17 ordered mesoporous silica (OMS) materials, 204 Aerosol, 16–17 Allergic rhinitis, 183 Animal model systems, CR modeling cat, 81–82 dog, 79–81 intestinal transit gastric emptying, 73–76 gastric pH, 72–73 gastric smooth muscle, 72 metabolism, 78 microflora, 77–78 small intestine pH, 76 small intestine transit, 76–77 transport, 78 monkey, 82 pharmacoscintigraphic studies, 83–85 physiological factors, 71 pig/minipig, 82 rat/mouse, 78–79 Anti-infectives, drug release, 56–58 Arthritis, 183–184 Avinza™. See Spheroidal oral drug absorption system (SODAS™) B Bioadhesion polymers, 340 Bioinspired gastric retentive formulations, 374 Biomarkers cancer therapy, 67
capsule drug delivery, 294 defined, controlling drug release, 58–60 Buccal drug delivery advantages and challenges, 333–334 described, 30–31 drug release mechanisms classification, 335, 336 matrix diffusion and erosion systems, 337 types, matrix erosion systems, 336 fast dissolving film strip composition, 349 manufacturing pr
Data Loading...
